What is the best tech stack for a clinical research site in 2027?

A site that enrolls well and still loses money

Picture a three-coordinator dedicated research site running eleven concurrent protocols. Enrollment is fine — the principal investigator has a good referral panel, the coordinators are experienced, and screen-fail rates sit in a defensible range. On paper this is a healthy site. In practice it is bleeding, and nobody can point at where.

Here is the anatomy of the bleed. Each of the eleven protocols has its own visit schedule, its own procedure list, its own stipend structure, and its own budget with per-visit line items, holdbacks, and pass-through costs. The coordinators track visit windows in a shared spreadsheet with a tab per study. The regulatory binders live in a mix of three-ring binders and a network drive folder. Source worksheets are printed, filled by hand, then re-keyed into whichever electronic data capture system that sponsor mandates — Medidata Rave for four studies, Veeva CDMS for three, Oracle Clinical One for two, and two smaller sponsors on systems nobody has seen before. Invoicing happens when the office manager gets to it, usually quarterly, reconstructed from the spreadsheets.

The failure is not effort. It is that no single system knows what happened. A subject completes a Week 12 visit with an ECG, a PK draw, and a stipend payment. That visit is simultaneously an operational event (was it in window?), a data event (does it reconcile to the EDC?), a compliance event (is the source signed and attributable?), and a revenue event (which contracted line item does it bill against, and did the sponsor pay it?). When those four views live in four disconnected places, the revenue view is the one that quietly degrades, because it is the only one nobody outside the site is chasing. Sponsors will hound you for EDC query resolution. Monitors will hound you for regulatory documents. No one hounds you to invoice them.

This is why the stack for a research site looks nothing like the stack for a discovery lab, and why "we're a healthcare business so we need an EHR" is the wrong starting frame. A discovery lab generates novel data and needs an electronic lab notebook and a LIMS to track samples and experiments. A clinical practice sees patients and needs an EHR plus practice management plus revenue cycle. A research site does neither. It executes protocols other organizations designed, on humans it recruited and consented, against a visit calendar it did not write, and bills per milestone to a sponsor that pays on a delay. The system of record has to be the thing that knows the visit schedule, because the visit schedule *is* the business model.

How the operational spine actually works

The site CTMS is the hub, and understanding why requires following a single subject from first contact to collected cash.

A candidate enters through recruitment — a marketplace like SubjectWell, a condition-matching service like Antidote or Clara Health, an ad-to-landing-page funnel the site runs itself, or the site's own patient database. Pre-screening logic knocks out obvious ineligibles before a coordinator spends time on a phone call. Survivors get scheduled for a screening visit. That handoff — lead to scheduled screening — is where a lot of sites lose people, and it is a tracked conversion, not an afterthought.

At the screening visit, e-consent runs first: a Part 11-compliant signature bound to the *currently IRB-approved* version of the consent form. That version binding matters enormously and is a common inspection finding when it fails. The consent lands in the eRegulatory system as part of the investigator site file. The subject is then enrolled in the CTMS against a specific protocol, which immediately generates the entire visit calendar — every scheduled visit, every window, every required procedure — from the protocol template.

From there the calendar drives everything. Each visit is a work order: here are the procedures, here is the window, here is the source document to complete. eSource captures that data electronically at the point of care, timestamped and signed, replacing the paper worksheet that used to get lost or become illegible. The captured source then reconciles into the sponsor's EDC — sometimes via export, more often via a coordinator re-keying it, which is exactly why an eSource system with a clean export and a well-designed form structure saves real hours per visit.

Simultaneously the completed visit becomes a financial object. It maps to a contracted budget line, becomes invoiceable to the sponsor, and triggers a participant stipend disbursement through a payment rail like Greenphire's ClinCard so the site never fronts cash or cuts a check. Two payment directions, two different rails, one triggering event.

The architectural point: recruitment feeds the CTMS, the CTMS generates the calendar, the calendar drives both data capture and billing, and the eRegulatory layer runs alongside as the compliance backbone rather than downstream of anything. Break any edge in that graph and you get a specific, predictable failure — break recruitment-to-CTMS and leads evaporate untracked; break calendar-to-financials and you under-invoice; break eSource-to-EDC and you drown in queries.

What the layers cost and how they scale

Concrete ranges, because "it depends" is not a budget.

Site CTMS. Clinical Conductor by Advarra is the dominant enterprise site CTMS, built for multi-site networks needing centralized oversight and cross-location financial reporting; it runs roughly $2,000–$6,000+ per month depending on site count and modules. RealTime-CTMS sits in the mid-market at roughly $1,000–$3,000 per month and carries a genuinely good text-message recruitment and scheduling layer. CRIO is quoted per-site/per-study, typically a few hundred to a couple thousand per site per month, and its structural advantage is fusing CTMS and eSource into one product — for a single or mid-size site that removes an integration you would otherwise pay for twice.

eRegulatory / eSource / eISF. Florence Healthcare's eBinders is the most widely deployed site-side eRegulatory and eISF platform, with eHub handling remote document exchange and signature with sponsors and CROs; budget roughly $300–$1,500 per month per site by document and user volume. Veeva SiteVault offers a free-to-the-site base eReg/eISF tier, with paid eConsent and connected modules — attractive when sponsors already run Veeva. If your CTMS is CRIO or RealTime, the matching eSource module keeps source capture in the same system and avoids a second login.

e-Consent. Usually a module of the eReg platform already in place; roughly $100–$500 per month per site when licensed separately.

Recruitment. SubjectWell operates a managed, pay-per-randomized-patient marketplace, so cost scales with enrollment rather than seats. If you want to own the funnel instead, HubSpot Marketing runs roughly $800–$3,600 per month at scale and Twilio is usage-based at pennies per message; Mautic is the open-source alternative if you have the technical staff. Paid advertising spend is the genuinely variable line and frequently exceeds every software line combined.

Sponsor EDC. Zero licensing cost to the site — the sponsor or CRO supplies it. Your cost is training and credential management across many concurrent systems, and the re-keying labor per visit.

Accounting and BI. QuickBooks Online at roughly $90–$200 per month fits single and mid-size sites. Large SMOs move to Sage Intacct, roughly $10,000+ per year, for multi-entity consolidation and revenue recognition that actually matches deferred milestone billing. Power BI at $14 per user per month reads from CTMS and accounting exports; smaller sites reasonably skip it and use native CTMS dashboards.

Rolling that up by scale: a single site with one to three coordinators and a handful of concurrent studies runs roughly $1,500–$4,000 per month in owned software. A regional group of three to eight sites with dedicated recruitment staff runs roughly $5,000–$15,000 per month. A large network or SMO with ten-plus sites runs roughly $20,000–$75,000+ per month all-in, with recruitment spend usually the largest and most volatile line.

The benchmark that matters more than any of these: roughly 80 percent of trials miss enrollment timelines. Against that backdrop, software cost is almost never the constraint — an under-enrolling study costs more in a month of missed milestone revenue than the entire stack costs in a year. Size the stack to protect enrollment and billing accuracy, not to minimize the license line.

Trade-offs, alternatives, and adjacent site models

The single biggest architectural decision is integrated versus best-of-breed, and it maps almost cleanly to site size.

The integrated case: CRIO bundles CTMS and eSource; RealTime bundles CTMS, eSource, and recruitment messaging; Veeva bundles eReg, eConsent, and — on the sponsor side — CDMS. One vendor, one login, one support path, no reconciliation between systems that disagree about what a visit is. For a site with two or three coordinators, that consolidation is worth more than any individual feature, because there is nobody on staff whose job is integration maintenance.

The best-of-breed case: an enterprise network running twenty sites has genuinely different needs per layer. It wants Clinical Conductor's cross-site financial reporting, Florence's mature eHub sponsor connectivity, a dedicated recruitment marketplace with its own patient database, Sage Intacct's multi-entity consolidation, and a warehouse feeding Power BI. At that scale someone *does* own integration, and the per-layer capability gap between "best" and "bundled" is large enough to justify the seams.

The failure mode is picking the wrong side of that line — specifically, a small site buying enterprise. A two-coordinator site that licenses Clinical Conductor typically drowns in configuration, uses a tenth of it, and keeps a shadow spreadsheet anyway. Match CTMS to scale and move up only when multi-site oversight genuinely demands it.

Adjacent site models change the calculus in instructive ways:

Hospital and academic medical center sites sit inside an Epic EHR and an institutional grants and compliance environment. They frequently run an institutional CTMS — OnCore is common in academia — rather than a commercial site CTMS, use the institution's own IRB instead of a central one, and carry a problem no freestanding site has: reconciling study billing against the hospital's clinical billing so research-related procedures are not double-billed to Medicare. That reconciliation is a compliance exposure, not just an accounting chore, and it drives the whole architecture.

Private practices running trials on the side — a cardiology or dermatology group with three or four studies adjacent to clinical care — need the lightest viable setup: CRIO or RealTime, Florence or SiteVault, sponsor recruitment support plus their own patient panel, and strict separation of trial books from clinical revenue in QuickBooks. The mistake here is trying to run research out of the practice's existing EHR and practice-management stack, which has no concept of a protocol visit window or a milestone budget line.

Acquisitive site networks face a migration problem more than a selection problem. Standardizing acquired sites onto a common CTMS and eReg backbone is what makes oversight tractable, and the hard work is moving each acquisition off legacy paper or mismatched systems without losing regulatory continuity mid-study.

Decentralized and hybrid trial elements — remote visits, telehealth check-ins, direct-to-patient shipping, wearables — increasingly ride on top of this same spine rather than replacing it. They add sponsor-supplied tooling the site must operate, which reinforces the same lesson as EDC: the site does not control every system it touches, so the systems it *does* control should be the ones that hold the operational and financial truth.

Pitfalls that quietly destroy site economics

Treating eRegulatory as document storage. Sites that dump PDFs into a shared drive, or use a generic document tool without enforced versioning, Part 11 signatures, and binding to the current IRB-approved form, fail inspections on document control. The fix is a purpose-built eISF and — this is the part people skip — actually using its workflow instead of routing around it. A compliance system everyone bypasses is worse than no system, because it creates a false record of control.

No recruitment engine at all. A site relying solely on the PI's existing patient list under-enrolls, misses timelines, and quietly drops off sponsor site-selection lists. That last consequence is the expensive one: it is invisible, it compounds, and by the time you notice fewer feasibility questionnaires arriving, the reputation damage is already priced in. Build an actual funnel and treat screen-to-enroll conversion as a primary operating metric.

Losing milestone-to-payment reconciliation. Because sponsor payment is per-visit, deferred, and holdback-laden, sites that do not tie performed visits to contracted budget lines leave real money uncollected and — worse — cannot tell which studies are profitable. Without that, budget negotiation on the *next* protocol is guesswork. The fix is mapping every completed visit to its budget line in the CTMS financial module, running aging on sponsor receivables monthly, and never waiting until study close-out when the trail has gone cold.

Ignoring the eSource-to-EDC re-keying tax. Coordinators entering the same data twice is not a minor annoyance; across a busy site it is a meaningful fraction of coordinator capacity, and it is where transcription errors that become sponsor queries originate. You cannot eliminate it — the sponsor picks the EDC — but you can minimize it by designing eSource forms to mirror the EDC's field structure so re-keying is mechanical rather than interpretive.

Under-training on the systems you did not choose. Every new protocol may mean a new EDC, a new IRT system, and new sponsor portals. Sites that treat credential and training management as ad hoc lose days at study startup and generate avoidable protocol deviations. A simple owned registry of systems, credentials, and completed training per coordinator is unglamorous and pays back immediately.

Deploying everything at once. A realistic sequence: stand up the CTMS first and load every active protocol, visit calendar, and current subject roster, because the calendar is the spine everything else hangs on. Then migrate the investigator site file into the eRegulatory platform, enable Part 11 signatures, and launch the recruitment funnel. Only then wire CTMS financials to milestones, connect the participant payment rail, and build reporting on enrollment velocity, screen-fail rate, and payment aging. Roughly thirty days per stage for a small site. Reversing that order — starting with dashboards before the calendar is trustworthy — produces confident reporting on bad data.

Related questions

Do I need a CTMS if I only run two studies?

At two concurrent protocols spreadsheets are survivable but already risky. The moment you cross three or four, visit-window tracking and milestone billing across protocols exceed what a spreadsheet reliably does. A right-sized CTMS usually pays for itself the first time it catches an uninvoiced milestone.

Can I use my EHR as a research system?

No. An EHR has no concept of a protocol visit window, a screen-fail, a contracted budget line, or a milestone invoice. Hospital sites run an EHR *and* a CTMS, and spend real effort reconciling the two so research procedures are not billed to clinical payers.

How does a site stack differ from a biotech lab stack?

A discovery lab generates new data and centers on an electronic lab notebook and a LIMS for samples and experiments. A research site executes protocols others designed and centers on CTMS, eRegulatory/eSource, recruitment, and milestone billing — none of which a discovery lab touches.

Who pays for the participant payment platform?

Participant stipend platforms are typically funded per-study by the sponsor as a pass-through, while the site pays for its own CTMS financial module. The site's benefit is not fronting cash or cutting checks for per-visit stipends and travel reimbursement.

FAQ

Why can't a site choose its own EDC?

Because the sponsor or CRO that owns the study mandates it in the protocol. Coordinators enter data into whatever that study requires — commonly Medidata Rave, Veeva CDMS, or Oracle Clinical One. The site's job is managing credentials and training across many concurrent systems and capturing clean source data so re-keying is fast and error-free.

How do eRegulatory and eSource actually keep a site inspection-ready?

The eRegulatory system holds the investigator site file with enforced version control, Part 11-compliant electronic signatures, and a complete audit trail, so a monitor or inspector gets the current signed version instantly. eSource captures visit data electronically at the point of care with timestamps and attribution, eliminating the lost or illegible paper worksheets behind many common findings.

Should a single site start with CRIO or Clinical Conductor?

Almost always CRIO or RealTime-CTMS. CRIO bundles CTMS and eSource into one product, removing a costly integration and fitting a small team's staffing and budget. Clinical Conductor is the right choice once you operate multiple locations and need centralized oversight, network reporting, and multi-entity financials that a single site cannot use.

What single metric best predicts a site's revenue health?

Screen-to-enroll conversion, paired with payment aging. The first tells you whether the recruitment engine works; the second tells you whether completed work is actually converting to collected cash. A site can look busy on both enrollment and visit volume while failing badly on the second.

How long does it realistically take to stand up this stack?

Roughly ninety days for a small site if sequenced properly: CTMS and visit calendars first, then eRegulatory migration plus Part 11 signatures and the recruitment funnel, then financial mapping, payment rails, and reporting. Attempting all three stages simultaneously is the most common cause of a half-configured system nobody trusts.

Does an integrated single-vendor stack ever stop making sense?

Yes — typically past eight to ten sites, when cross-location financial consolidation, sponsor connectivity depth, and centralized recruitment each demand a specialist system. At that point you have staff who own integration, and the per-layer capability gap justifies the seams.

Sources

• https://www.fda.gov/regulatory-information/search-fda-guidance-documents/part-11-electronic-records-electronic-signatures-scope-and-application
• https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-11
• https://www.advarra.com/software/clinical-conductor-ctms/
• https://www.florencehc.com/
• https://sites.veeva.com/
• https://clinicalresearch.io/
• https://www.realtime-ctms.com/
• https://www.medidata.com/en/clinical-trial-products/clinical-data-management/edc-systems/
• https://www.oracle.com/life-sciences/clinical-one/
• https://clinicaltrials.gov/

Related on PULSE

• [The Open-Weight LLM Stack for Academic Research Labs in 2027](/knowledge/tk0541)
• [Building a Clinical Trial Management System: Electronic Data Capture and Compliance with REDCap and Python](/knowledge/tk0428)
• [What is the best tech stack for an excavation or site work contractor in 2027?](/knowledge/tk0162)
• [Top 10 Static Site Generators for Portfolio-Building Developers](/knowledge/tk0468)